EU medicines committee recommends Aumseqa for lung cancer
The committee also recommended Baxfendy for insufficiently controlled high blood pressure and Zybrivo for adults with non-squamous non-small cell lung cancer, advancing the medicines toward EU authorization.
In this article
The European Medicines Agency’s human medicines committee recommended Aumseqa (aumolertinib) for non-small cell lung cancer at its November 9–12 meeting. The recommendation is not itself an authorization to market the medicine in the European Union.
The committee also recommended Baxfendy (baxdrostat) for high blood pressure that is insufficiently controlled, and gave a positive opinion on Zybrivo (sintilimab) for adults with non-squamous non-small cell lung cancer, a type of lung cancer.
Aumseqa received an earlier positive opinion in December 2025, and aumolertinib was authorized for medical use in the EU in February 2026. In a phase III trial, baxdrostat added to standard treatment reduced blood pressure more than placebo at 12 weeks. Hyperkalaemia was noted in another trial.
The agency’s meeting announcement sets out the recommendations.
Share
Follow AveNews
Earlier in Science
EarthPhilanthropic groups pledge $73 million to rainforest fund
The pledges announced during COP31 in Antalya, Turkey, bring philanthropic commitments to the Tropical Forest Forever Facility to $88 million, as the fund seeks the capital needed to start.
2 min
EarthCrews sink SS United States off Florida to create an artificial reef
The liner was deliberately sunk off Destin on 11 November, after failed efforts to preserve it above water. Okaloosa County acquired the ship as an alternative to scrapping it and converted it into a reef.
2 min
SpaceUS Senate panel proposes $24.87 billion for NASA
The spending proposal includes $7.43 billion for science and would integrate Mars Sample Return into Moon-to-Mars as a test for human exploration.
2 min
